Manufacturing roundup: Andelyn Biosciences opens new facility in Ohio; Novo warns of Ozempic counterfeit

An­de­lyn Bio­sciences, a cell and gene ther­a­py CD­MO, has opened a new man­u­fac­tur­ing head­quar­ters in Colum­bus, OH.

The new 180,000-square-foot fa­cil­i­ty is home to An­de­lyn’s man­u­fac­tur­ing space as well as lab­o­ra­to­ries and of­fices, tripling the CD­MO’s amount of space. Ac­cord­ing to An­de­lyn CEO Wade Mace­done in a re­lease, the new fa­cil­i­ty will have 16 man­u­fac­tur­ing suites with mul­ti­ple ca­pa­bil­i­ties as well as qual­i­ty con­trol labs, ware­hous­ing space and of­fice fa­cil­i­ties to house its cor­po­rate head­quar­ters. The cost of the fa­cil­i­ty was not im­me­di­ate­ly dis­closed.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN